which mutations benefit most from parp inhibitors in prostate cancer?
Published 4 months ago • 46 plays • Length 0:31Download video MP4
Download video MP3
Similar videos
-
3:13
impact of specific mutations on parp inhibition in prostate cancer
-
1:01
choosing the correct parp inhibitor for prostate cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
4:02
the emerging role of parp inhibitors in prostate cancer
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
0:57
when is the optimal time to use parp inhibitors in prostate cancer patients?
-
0:58
biomarkers associated with parpi response in patients with castration-resistant prostate cancer
-
1:25
parp inhibitors: their applications and efficacy against prostate cancer
-
2:48
assessing parp inhibition and brca1/2 as a prognostic biomarker in mcrpc
-
1:38
updates in parp inhibition for ovarian cancer
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
1:21
combining a parp and pd-l1 inhibitor to treat prostate cancer
-
35:38
parp inhibitor combination regimens for prostate cancer management
-
12:07
parp inhibitors in brca1/2-mutated patients in prostate cancer
-
38:47
parp inhibitors and their evolving role for the treatment of prostate cancer
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
4:12
parp inhibitors
-
1:52
parpi for somatic brca1/2 and other dna repair gene mutations in women with metastatic breast cancer